- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Teva launches generic drug for cystic fibrosis patients
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
NORTH WALES, Pa. Teva Pharmaceutical Industries has introduced a generic drug for lowering patients’ blood pressure, the world’s largest manufacturer of generic drugs said Monday.
Teva introduced clonidine transdermal system, a generic version of Boehringer Ingelheim’s Catapres-TTS. The drug is available in 0.1 mg, 0.2 mg and 0.3 mg strengths and comes in the form of a patch designed for daily application.
The drug has annual sales of around $297 million, according to IMS Health.